YWYun-Liang Wang

Yun-Liang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yun-Liang Wang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Jun-Xiang Li

    Department of Gastroenterology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, China

    4 shared publications
  • Chun-E Xie

    Department of Gastroenterology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, China

    3 shared publications
  • Yang Zhang

    Department of Gastroenterology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, China

    3 shared publications
  • Lin-Heng Wang

    Department of Gastroenterology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, China

    2 shared publications
  • Xiao-Jun Shi

    Department of Gastroenterology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, China

    2 shared publications
  • Chang Zhang

    1 shared publication

Latest Publications

  • Open Access

    Research Progress on Nanoformulations Based on Active Components from Traditional Chinese Medicine for MASLD

    by Zi-Xiu Gou, Ning-Wei Li, Jun-Yi Yao, Yun-Liang Wang

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease with rising prevalence and disease burden. However, despite recent therapeutic advances, effective and broadly applicable treatment options remain limited, prompting continued efforts to develop novel therapeutic agents. Traditional Chinese Medicine (TCM) has attracted growing interest in MASLD management because its bioactive compounds can target multiple pathogenic processes. However, many TCM-derived compounds are limited by poor solubility, low bioavailability, and insufficient tissue specificity. Nanotechnology-based formulations enable controlled release and targeted delivery, offering a strategy to improve the utilization and therapeutic efficacy of TCM-derived active ingredients against MASLD. Based on a structured literature search across four databases, 45 representative studies were included and narratively synthesized according to nanoplatform type, design features, and mechanism-related therapeutic actions. Compared with previous broader reviews on TCM nanomedicine or MASLD-related nanotherapies, this review particularly emphasizes MASLD-oriented TCM nanoformulations from the perspectives of platform classification, design features, and mechanism-related therapeutic actions. We also discuss current challenges and future directions for clinical translation.


  • Open Access

    Study protocol for a randomized, double-blind, double-simulation, positive drug-parallel controlled trial investigating the impact of modified Linggui Yinchen decoction on ApoA1/LCAT activity in the treatment of obese MAFLD

    by Juncong Hu, Yingdi Qu, Junyi Yao, Yunliang Wang

    Objective: Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), was renamed in 2020 to emphasize its metabolic nature. Presently, modern medicine faces challenges in providing effective treatments for MAFLD. In contrast, traditional Chinese medicine (TCM) has demonstrated potential in alleviating clinical symptoms and improving liver function. Modified Linggui Yinchen Decoction (M-LGYCD) is derived from Lingguizhugan and Yinchenhao decoctions. This blend is specifically designed to invigorate the spleen, soothe the liver, and alleviate the stagnation of turbid yin. Methods: This study develops a randomized, double-blind, positive drug-controlled trial protocol to investigate the effects of M-LGYCD on apolipoprotein A1 (ApoA1)/lecithin cholesterol acyltransferase (LCAT) activity in reverse cholesterol transport. It is planned to recruit 124 outpatient and inpatient obese MAFLD patients with syndrome of spleen deficiency and liver depression, along with turbid yin stagnation, for a period of 8 weeks. The research goal is to assess the efficiency and safety of M-LGYCD by analyzing liver and kidney functions, blood lipids, metabolic indicators, and patient-reported symptoms before and after treatment. In addition, plasma ApoA1/LCAT activity measurement, transcriptome analysis, and lipid metabolome analysis will be conducted to elucidate the therapeutic mechanism of M-LGYCD and reveal the connotation of spleen deficiency and liver depression, along with turbid yin stagnation syndrome. Discussion: This study is expected to provide a scientific basis and new therapeutic ideas for the TCM treatment of obese MAFLD.

  • Open Access

    Comparison of “Exterior-interior Pairing of the Lung and Large Intestine” and “Gut-lung Crosstalk” Based on COVID-19

    by Yunliang Wang, Yan Zhang

    The infection of SARS-CoV-2 has triggered the COVID-19 pandemic. In addition to the fever and respiratory symptoms in the process of coronavirus infections, gastrointestinal symptoms, especially diarrhea, are prominent features of its acute infection and long COVID. The associations between the lung and large intestine have been demonstrated by Western medicine in aspects such as tissue origin, microflora homeostasis, mucosal immunity, renin-angiotensin system (RAS) and autonomic nervous system as well, which are considered as the evidence of material basis and potential regulatory mechanisms for “gut-lung crosstalk (肺肠串扰)” in COVID-19. We have noticed that probiotics and other preparations can regulate the intestines, and further treat COVID-19 with effective and gratifying results. In the system of traditional Chinese medicine (TCM), there’s a term of “exterior-interior pairing of the lung and large intestine (肺与大肠相表里)”, showing an interconnection of the lung and the bowels. “Exterior-interior pairing of the lung and large intestine” is an important part of the theory of visceral activities proposed by ancient physicians through a long-term observation and practice. It’s considered that “lung” and “large intestine” are interconnected and mutually exterior-interior in the normal physical activities and the disease development, providing a theoretical basis for treating lung diseases and bowel diseases from the perspective of overall concept. The study aims to compare the term of “exterior-interior pairing of the lung and large intestine” in TCM and “gut-lung crosstalk” in Western medicine regarding the development of COVID-19 and its intestinal symptoms, and provide more ideas for diagnosing and treating lung and bowel related diseases.


  • Open Access

    Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway

    by Yang Zhang, Xiao-Jun Shi, Jun-Xiang Li, Lin-Heng Wang, Chun-E Xie, Yun-Liang Wang

    Background: Hepatocellular carcinoma (HCC) is a highly invasive disease with a high mortality rate. Our previous study found that Chenodeoxycholic acid (CDCA) as an endogenous metabolite can enhance the anti-tumor effect. Sorafenib has limited overall efficacy as a first-line agent in HCC, and combined with CDCA may improve its efficacy.Methods: HepG2 cells and Balb/c nude mice were used respectively for in vitro and in vivo experiments. Flow cytometry, Western blotting, HE and immunohistochemical staining and immunofluorescence were used to study the effects of CDCA combined with sorafenib on HepG2 cell growth and apoptosis-related proteins. Magnetic bead coupling, protein profiling and magnetic bead immunoprecipitation were used to find the targets of CDCA action. The effect of CDCA on EGFR/Stat3 signaling pathway was further verified by knocking down Stat3 and EGFR. Finally, fluorescence confocal, and molecular docking were used to study the binding site of CDCA to EGFR.Results: In this study, we found that CDCA enhanced the effect of sorafenib in inhibiting the proliferation, migration and invasion of HepG2 cells. Magnetic bead immunoprecipitation and protein profiling revealed that CDCA may enhance the effect of sorafenib by affecting the EGFR/Stat3 signaling pathway. Further results from in vitro and in vivo gene knockdown experiments, confocal experiments and molecular docking showed that CDCA enhances the efficacy of sorafenib by binding to the extracellular structural domain of EGFR.Conclusion: This study reveals the mechanism that CDCA enhances the inhibitory effect of sorafenib on HepG2 cell growth in vitro and in vivo, providing a potential new combination strategy for the treatment of HCC.


  • Open Access

    Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis

    by Yang Zhang, Jun-Xiang Li, Yun-Liang Wang

    Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with a pathogenesis that has not been fully elucidated. With the development of the theory of the gut-liver axis and the deepening of related research, the role of the intestinal tract in the pathogenesis of NAFLD has been investigated more. Intestinal microbiota, intestinal metabolites, and intestinal epithelial and immune-based barriers constitute the intestinal environment, which uses crosstalk to maintain the homeostasis of the intestinal environment. This paper reviews the progress in the study of intestinal microbiota, intestinal environment, and NAFLD and suggests that repair of intestinal functional balance may be a new idea for early prevention and intervention of NAFLD.


  • Open Access

    Primary duodenal tuberculosis misdiagnosed as tumor by imaging examination: A case report

    by Yang Zhang, Xiao-Jun Shi, Xian-Cui Zhang, Xing-Jie Zhao, Jun-Xiang Li, Lin-Heng Wang, Chun-E Xie, Yu-Yue Liu, Yun-Liang Wang

    Primary duodenal tuberculosis is very rare. Due to a lack of specificity for its presenting symptoms, it is easily misdiagnosed clinically. Review of the few case reports and literature on the topic will help to improve the overall understanding of this disease and aid in differential diagnosis to improve patient outcome. A 71-year-old man with a 30-plus year history of bronchiectasis and bronchitis presented to the Gastroenterology Department of our hospital complaining of intermittent upper abdominal pain. Initial imaging examination revealed a duodenal space-occupying lesion; subsequent upper abdominal contrast-enhanced computed tomography indicated duodenal malignant tumor. Physical and laboratory examinations showed no obvious abnormalities. In order to confirm further the diagnosis, electronic endoscopy was performed and tissue biopsies were taken. Duodenal histopathology showed granuloma and necrosis. In-depth tuberculosis-related examination did not rule out tuberculosis, so we initiated treatment with anti-tuberculosis drugs. At 6 mo after the anti-tuberculosis drug course, there were no signs of new development of primary lesions by upper abdominal computed tomography, and no complications had manifested. This case emphasizes the importance of differential diagnosis for gastrointestinal diseases. Duodenal tuberculosis requires a systematic examination and physician awareness.


  • Open Access

    Gegen Qinlian Decoction Attenuates High‐Fat Diet‐Induced Steatohepatitis in Rats via Gut Microbiota

    by Yi Guo, Pang-Hua Ding, Li-Juan Liu, Lei Shi, Tang-You Mao, Jun-Xiang Li, Yun-Liang Wang

    Gut microbiota play an important role in modulating energy contribution, metabolism, and inflammation, and disruption of the microbiome population is closely associated with chronic metabolic diseases, such as nonalcoholic fatty liver disease (NAFLD). Gegen Qinlian decoction (GGQLD), a well‐known traditional Chinese herbal medicine (CHM), was previously found to regulate lipid metabolism and attenuate inflammation during NAFLD pathogenesis. However, the underlying mechanism of this process, as well as how the gut microbiome is involved, remains largely unknown. In this study, we investigated the effect of varying doses of GGQLD on the total amount and distribution of gut bacteria in rats fed a high‐fat diet (HFD) for 8 weeks. Our analysis indicates that Oscillibacter and Ruminococcaceae_g_unclassified are the dominant families in the HFD group. Further, HFD‐dependent differences at the phylum, class, and genus levels appear to lead to dysbiosis, characterized by an increase in the Firmicutes/Bacteroidetes ratio and a dramatic increase in the Oscillibacter genus compared to the control group. Treatment with GGQLD, especially the GGQLL dose, improved these HFD‐induced changes in intestinal flora, leading to increased levels of Firmicutes, Clostridia, Lactobacillus, bacilli, and Erysipelotrichales that were similar to the controls. Taken together, our data highlight the efficacy of GGQLD in treating NAFLD and support its clinical use as a treatment for NAFLD/NASH patients.


  • Open Access

    Targeting Sirt1 in a rat model of high‑fat diet‑induced non‑alcoholic fatty liver disease: Comparison of Gegen Qinlian decoction and resveratrol

    by Yi Guo, Jun‑Xiang Li, Tang‑You Mao, Wei‑Han Zhao, Li‑Juan Liu, Yun‑Liang Wang

    The present study aimed to explore the mechanism of action of Gegen Qinlian decoction (GGQLD) in experimental non‑alcoholic fatty liver disease (NAFLD). A total of 30 rats were randomly divided into five groups: The chow, model, high‑ and low‑dose GGQLD (GGQLD‑H and GGQLD‑L, respectively) and resveratrol (Resl) groups, and were treated with saline, GGQLD and Resl when a model of high‑fat diet (HFD)‑induced NAFLD was established. Blood lipid and liver enzymes were detected following treatment for 8 weeks and liver tissue pathology was observed using Oil Red O and haematoxylin and eosin staining. Furthermore, the liver protein and mRNA expression of sirtuin (Sirt)1, peroxisome proliferator‑activated receptor‑γ coactivator (PGC)‑1α and nuclear factor κ‑light‑chain‑enhancer of activated B cells (NF‑κB) were measured using western blotting and reverse transcription‑quantitative polymerase chain reaction. Compared with the chow group, the model group demonstrated significantly increased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (P<0.01). GGQLD doses and Resl attenuated the elevated serum ALT and AST levels. GGQLD‑H and Resl significantly increased the serum high‑density lipoprotein cholesterol level compared with that in the model group (P<0.01), while GGQLD‑L and Resl significantly decreased serum low‑density lipoprotein cholesterol levels (P<0.01). The GGQLDs and Resl groups revealed an evident improvement in Sirt1 protein and mRNA expression. Although GGQLD and Resl significantly decreased NF‑κB gene expression compared with the model group (P<0.01), the effect on NF‑κB protein expression was not significant. Furthermore, the PGC‑1α gene and protein expression in the HFD rat group slightly decreased compared to the levels in the chow group, but the decrease was insignificant. However, an evident increase in PGC‑1α mRNA expression was observed in the GGQLD‑H group compared with the model group (P<0.01). Histological staining revealed that GGQLD and Resl decreased the lipid droplets in hepatocytes and normalized steatosis in rats fed with a HFD. The results indicated that GGQLD treatment may be a potent strategy for managing NAFLD by managing lipid metabolism and inflammatory and histological abnormalities by triggering the Sirt1 pathway.


    • 1 January 2014
      • Vol. 34  (1) , 15-9

    [Treatment of nonalcoholic steatohepatitis by Jianpi Shugan Recipe: a multi-center, randomized, controlled clinical trial].

    by Jun-Xiang Li, Yun-Liang Wang, Min Liu, Shao-Neng Liu, Chun-Jun Xu, Jing Zhao, Rui Shi, Dong-Mei Su, Li Zhuge, Xi Chen, et al.

    To evaluate the efficacy and safety of Chinese medicine (CM) intervention in the treatment of nonalcoholic steatohepatitis (NASH) from liver enzyme (ALT), imaging (the liver/spleen CT ratio) and syndrome scores, and to establish standard methods for diagnosis and therapeutic efficacy evaluation with characteristics of CM. A multi-center, stratified randomized, parallel controlled, blindness-method evaluated, superiority trial was performed. Totally 204 patients were randomly allocated into two groups, 102 patients in the experimental group (treated with CM) and 102 patients in the control group [treated with Western medicine (WM)]. The alanine aminotransferase (ALT), liver/spleen CT ratio, and clinical symptoms were observed in both groups. Of the randomly allocated 204 cases from 4 hospitals, 3 patients were rejected, and 25 were lost. Totally 176 cases con- formed to the plan with complete follow-ups. After 3 months of treatment, syndrome scores and the improvement of partial clinical symptoms (fatigue and sallow complexion) were superior in the experimental group to those in the control group (P < 0.05). After 3 months of follow-up, the syndrome scores and improvement of partial clinical symptoms (fatigue and sallow complexion) were superior in the experimental group to those in the control group (P < 0.05). There was no statistical difference in improving liver enzymes or the liver/spleen CT ratio between the two groups (P > 0.05). There were 4 adverse reactions/adverse events in the two groups in the process of treatment, mainly covering drug-induced liver injury, diarrhea, and epigastric distension. Adverse reactions had nothing to do with CM treatment. Jianpi Shugan Recipe had obvious efficacy in treatment of NASH. It could remove the liver fat and play a role in anti-inflammation and liver protection. It also could improve the indices of liver enzymes and the liver/spleen CT ratio effectively, which was superior to Polyene Phosphatidylcholine Capsule (PPC) in improving clinical symptoms, especially for such symptoms as fatigue and sallow complexion.